ArticlePloS one2025
Influence of bodyweight on prednisolone pharmacokinetics in dogs.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- ACVIM-endorsed statement: consensus statement and systematic review on guidelines for the diagnosis and treatment of chronic inflammatory enteropathy in dogs.Journal of veterinary internal medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarger dogs may be at greater risk of prednisolone side effects, yet there is limited research about how bodyweight affects prednisolone pharmacokinetics in dogs. HYPOTHESIS/
objectivesTo describe the relationship between prednisolone dose, bodyweight, body surface area (BSA) and prednisolone area under the curve (AUC) in dogs receiving prednisolone for medical reasons. ANIMALS: 25 client owned dogs receiving prednisolone for medical reasons.
methodsObservational population pharmacokinetic study. Liquid chromatography tandem mass spectrometry was used for plasma prednisolone quantification. Data analysis was conducted in a two-stage approach using non-compartmental modelling. A Bayesian non-linear regression model described the relationship between AUC over 8 hours ([Formula: see text]ng·min/mL), bodyweight and prednisolone dose.
resultsFrom the allometric scaling model of the form AUC8h = A · BW B, the scaling exponent [Formula: see text] was.83 (90% credible interval (CrI):.60-1.06) and the coefficient [Formula: see text] was 22.8 (90% CrI: 11.8-43.4). This model suggests that equivalent exposure would be obtained using an intermediate strategy between BSA and bodyweight dosing, but the total evidence provided was relatively weak. CONCLUSIONS AND CLINICAL IMPORTANCE: Evidence was obtained regarding the nonlinear relationship between prednisolone pharmacokinetics and bodyweight in dogs; however, this model is currently too imprecise for clinical dose determination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.